Wockhardt LtdNSE:WOCKPHARMA
Current view Q4 2026
Makes medicines and its own novel antibiotic. The turnaround is real - profit back at 317 cr and margins tripled - but the whole story now rests on Zaynich, a just-FDA-approved drug that isn't selling yet.
Latest exchange filings last 5 · 5 after Q4 2026
- 25 Aug ’26Received 21 Aug 2026 customs order imposing ₹5 crore penalty and ₹10 crore redemption fine on Wockhardt for API misclassification. ↗
- 25 Aug ’26Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (LODR) Regulations, 2015, we enclose herewith a copy of newspaper … ↗
- 10 Aug ’26Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 10 Aug ↗
- 10 Aug ’26Shareholder Meeting / Postal Ballot-Outcome of AGM 10 Aug ↗
- 10 Aug ’26Crisil report for June 30, 2026 shows no deviation in Wockhardt’s QIP proceeds use. ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q4 2026
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q4 2026
| Metric | This year vs lastYoY · vs Q4 2025 | vs the quarter beforeQoQ, sequential · vs Q3 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +29.9% | +8.7% | +8.4% | +4.5% |
| Operating profit | ▲ +251.6% | +27.1% | +68.4% | −5.8% |
| EPS | ▲ +763.6% | +181.5% | +46.1% | −22.8% |
| PAT | ▲ +464.4% | +168.8% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +29.9%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Weak41/100
Growing fast — and the market has noticed. Profit per share grew 46% a year, and buyers now pay more for each rupee of it than they did a year ago. Some of the re-pricing has already happened.
₹2,188 → ₹4,375 needs the P/E at 107× — it is 167× today, and has ranged 86× to 507× over the last 5 years. The rest would come from earnings growing as they have.
What you pay for its profitlog scale · 5-year range
Tripling needs 161× — it has traded there — high was 507×.
Target capped at 46× — its 116× five-year average came from near-zero earnings.
At ₹604 the price-tag on its earnings reaches the 46× it is being projected toward — the point where being cheap against that yardstick is used up.
Re-rated already, on growth that doesn't fully back it.
How this is calculated
This is arithmetic, not a forecast — Return = ΔEPS × ΔMultiple. It says what would have to be true, not how likely it is, and "earnings keep growing at this rate for three more years" is the assumption doing the most work. This is a large-cap at ₹32,805 cr, so the odds of a re-rate are not fighting its own size.
Why the target is capped at 46×. This company averaged 116× over five years, but a multiple that high comes from near-zero earnings rather than from what buyers chose to pay — projecting a return to it would price in the collapse, not the recovery. 46× is what a 46% grower supports.
Growth rate used: 46.1% — the weakest of EPS / Sales / Op-profit from 3-year EPS CAGR. Latest quarter reads 60%.
How it compares with its rivals Healthcare · 6 of 159 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Wockhardt | ₹2,057 | 83.8× | ₹33,427 Cr | 7.5% | +973.6% | +25.9% |
| Sun Pharma.Inds. | ₹1,853 | 35.1× | ₹4.45 L Cr | 20.5% | +6.0% | +10.5% |
| Divi's Lab. | ₹9,376 | 83.5× | ₹2.49 L Cr | 22.0% | +65.5% | +27.8% |
| Torrent Pharma. | ₹4,855 | 82.8× | ₹1.85 L Cr | 15.2% | +5.8% | +54.9% |
| Zydus Lifesci. | ₹1,155 | 23.7× | ₹1.15 L Cr | 21.1% | −35.1% | +22.0% |
| Cipla | ₹1,375 | 31.0× | ₹1.11 L Cr | 15.5% | −39.2% | +2.3% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | wider, but it has moved around a lot | operating margin 3% → 21% over 3 years |
|---|---|---|
| Did the profit turn into cash? | more than all of it — reserves released cash too | 63% last year, 108% over three · free cash flow ₹76 cr, positive in 4 of 5 years |
| Is the growth borrowed? | lightly borrowed | ₹2,233 cr — 0.45× its own equity (was 0.46×) |
| Is it being collected? | customers are paying faster | 64 days to collect, down 16 in a year · cash cycle 168 days |
| Who has been buying? | the promoters have held steady | promoters 49.1%, 55.1% → 49.1% over 2.8 years · FIIs 7.2% (−0.1) · DIIs 9.2% (−1.8) · shareholders 1,72,989 → 1,66,518 |
| What does it earn on its capital? | earns little on its capital | ROCE 7.5% · ROE 6.1% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
Against it
- Stock is trading at 6.73 times its book value
- The company has delivered a poor sales growth of 4.49% over past five years.
- Company has a low return on equity of -1.43% over last 3 years.
- Promoter holding has decreased over last 3 years: -9.31%
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.